medigraphic.com
Órgano de Difusión de la Asociación Académica Panamericana de Medicina Familiar A.C.

2008, Number 2

<< Back Next >>

Arch Med Fam 2008; 10 (2)

Alendronate-associated Esophageal Ulcer: A Case Report

Rascón-Sabido R, Sabido-Siglher AS, Soler-Huerta E

Language: Spanish
References: 15
Page: 33-36
PDF size: 89.40 Kb.


ABSTRACT

We present a the case of a female patient 76 years of age with hiatal hernia without staging background, with a diagnosis of osteoporosis, for which her Family Physician prescribed alendronate, suggested by the Endocrinologist. This originated a severe esophageal ulcer diagnosed by endoscopic and histopathologic studies. This case revealed the need for diagnostic research by the Family Physician prior to prescribing alendronate and suspending such a drug in patients who experience the primary side effects, with the purpose of avoiding sequelae.


REFERENCES

  1. Cooper C, Gehlbach S, Lidsay R. Prevention and Treatment of Osteoporosis: a clinician´s guide. London: Taylor and, Francis. 2005 p. 122 páginas

  2. Gaudio A, Morabito N. Pharmacological Management of Severe Postmenopausal Osteoporosis. Drugs & Aging, 2005; 22(5):405-417 .

  3. Langston AL, Ralston SH. Management of Paget's disease of bone. Rheumatology 2004;43: 955-959.

  4. Watts N, Freedholm D, Daifotis A.The clinical tolerability profile of alendronate. Int J Clin Pract Suppl. 1999;101:51-61.

  5. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy. 2005; 37(8):740-744.

  6. Liberman UI, Hirsch LJ. Esophagitis and alendronate. [letter]. N Engl J Med. 1996; 335 (14): 1069-1070.

  7. Castell DO. "Pill Esophagitis"-the case of alendronate [editorial]. N Engl J Med. 1996; 335 (14): 1058-1059.

  8. De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996 Oct 3; 335(14): 1016-21.

  9. Abraham SC, Cruz-Correa M,Lee LA, Yardley JH, Wu. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol. 1999 Dec;12(12):1152-1157.

  10. Larsen KO, Stray N, Engh V, Sandnes D. Esophageal lesions associated with diphosphonates Tidsskr Nor Laegeforen.2000;30;120(20):2397-2399.

  11. Harris ST, Gertz BJ, Genant HK, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodelling in early postmenopausal women. J Clin Endocrinol Metab 1993;76:1399-1406.

  12. Lieberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in menopausalosteoporosis. N Engl J Med 1995;333(22):1437-43.

  13. Maconi G, Porro GB. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1996; 90(10):1889-1890.

  14. Ferrari Junior AP, Domingues SH. Esophageal ulcer and alendronate. Sao Paulo Med J.1998;116(6):1882-1884.

  15. Reacciones adversas. Rev Panam Salud Publica. 2000;7(1):.57-57.




2020     |     www.medigraphic.com